Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001415889-24-000592 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-02 | CLDX | Martin Samuel Bates | SVP AND CFO | M - OptEx | $2.78 | +10.8K | 35.1K | +44% | +$29.9K |
| D | 2024-01-04 | 2024-01-02 | CLDX | Martin Samuel Bates | SVP AND CFO | M - OptEx | $0.00 | -10.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | M | A | 10,750 | $2.78 | 35,128 | D | — | — | |
| 2 | Derivative | Incentive Stock Option (Right to Buy) | 2024-01-02 | M | D | 10,750 | $0.00 | 0 | D | $2.78 · — to 2029-06-19 | 10,750 Common Stock | (F1) As of June 19, 2023, the option is fully vested. |